(Q46318553)

English

Lower urinary tract symptoms associated with benign prostatic hyperplasia: combined treatment with fesoterodine fumarate extended-release and tamsulosin--a prospective study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23221480

Lower urinary tract symptoms associated with benign prostatic hyperplasia: combined treatment with fesoterodine fumarate extended-release and tamsulosin--a prospective study (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23221480

prostatic hypertrophy

1 reference

based on heuristic

inferred from title

author name string

Charalampos Konstantinidis

1

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23221480

Michael Samarinas

2

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23221480

Sotirios Andreadakis

3

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23221480

Stylianos Xanthis

4

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23221480

Konstantinos Skriapas

5

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23221480

publication date

5 December 2012

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23221480

Urologia Internationalis

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23221480

90

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23221480

2

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23221480

156-160

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23221480

The natural history of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1159%2F000345050

21 January 2018

The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society

1 reference

https://api.crossref.org/works/10.1159%2F000345050

21 January 2018

Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.

1 reference

https://api.crossref.org/works/10.1159%2F000345050

21 January 2018

Overactive bladder in the male patient: bladder, outlet, or both?

1 reference

https://api.crossref.org/works/10.1159%2F000345050

21 January 2018

A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder

1 reference

https://api.crossref.org/works/10.1159%2F000345050

21 January 2018

Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1159%2F000345050

21 January 2018

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1159%2F000345050

21 January 2018

Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.

1 reference

https://api.crossref.org/works/10.1159%2F000345050

21 January 2018

Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers

1 reference

https://api.crossref.org/works/10.1159%2F000345050

21 January 2018

Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1159%2F000345050

21 January 2018

Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study

1 reference

https://api.crossref.org/works/10.1159%2F000345050

21 January 2018

Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms

1 reference

https://api.crossref.org/works/10.1159%2F000345050

21 January 2018

Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder

1 reference

https://api.crossref.org/works/10.1159%2F000345050

21 January 2018

Identifiers

10.1159/000345050

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23221480

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23221480

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46318553&oldid=2104566502"